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Binding of High-Mannose-Type Oligosaccharides and
Synthetic Oligomannose Clusters to Human Antibody
2G12: Implications for HIV-1 Vaccine Design
epitopes of these antibodies should provide valuable
insights into HIV-1 vaccine design.
Among the broadly HIV-1-neutralizing antibodies so
far identified, human monoclonal antibody 2G12 is the
only one that directly targets the surface carbohydrate
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Baltimore, Maryland 21201 antigen of HIV-1. Several pieces of evidence suggest
that the epitope of 2G12 is a unique cluster of high-
mannose-type oligosaccharides (oligomannose) on HIV-1
gp120. Initial mutational studies indicated that the oligo-Summary
mannose sugar chains at the N-glycosylation sites N295,
N332, N339, N386, N392, and N448 might be involvedHuman antibody 2G12 broadly neutralizes human im-
in 2G12 recognition [12]. Two recent studies further pro-munodeficiency virus type 1 (HIV-1) isolates and
posed that the epitope of 2G12 might consist of severalshows protective activity against viral challenge in ani-
Man1-2Man-linked moieties contributed by the oligo-mal models. Previous mutational analysis suggested
mannose sugar chains that form a unique cluster onthat 2G12 recognized a novel cluster of high-mannose
gp120 at sites N295, N332, and N392 [15, 16]. Systematictype oligosaccharides on HIV-1 gp120. To explore the
mutational studies suggested that peptide portions ofcarbohydrate antigen for HIV-1 vaccine design, we
gp120 are not directly involved in the binding of 2G12have studied the binding of 2G12 to an array of HIV-1
but serve primarily as a rigid scaffold to hold the oligo-high-mannose type oligosaccharides by competitive
mannose sugars in proximity to form a unique clusterELISAs and found that Man9GlNAc is 210- and 74-fold
[12, 15, 16]. Although high-mannose oligosaccharidemore effective than Man5GlcNAc and Man6GlcNAc in
moiety exists in some human glycoproteins, such a high-binding to 2G12. The results establish that the larger
density, clustering oligomannose structure as that pres-high-mannose oligosaccharide on HIV-1 is the favor-
ent on HIV-1 gp120 has not been found in any otherable subunit for 2G12 recognition. To mimic the puta-
tive epitope of 2G12, we have created scaffold-based human glycoproteins so far. Therefore, the unique car-
multivalent Man9 clusters and found that the galac- bohydrate antigenic structure on HIV-1 gp120 provides
tose-scaffolded bi-, tri-, and tetra-valent Man9 clusters an ideal template for designing a vaccine that may gen-
are 7-, 22-, and 73-fold more effective in binding to erate HIV-neutralizing antibodies but will not raise cross-
2G12 than the monomeric Man9GlcNAc2Asn. The ex- reactivity or autoimmune reactions in humans. As the
perimental data shed light on further structural optimi- first step toward a carbohydrate-based HIV-1 vaccine,
zation of epitope mimics for developing a carbohy- we describe in this paper our studies on the binding of
drate-based HIV-1 vaccine. 2G12 to typical HIV-1 high-mannose-type oligosaccha-
rides as well as synthetic oligomannose clusters that
mimic the epitope of 2G12. We have found that Man9Glc-Introduction
NAc is the most efficient subunit for 2G12 binding among
the high-mannose-type oligosaccharides tested. TheThe worldwide epidemic of human immunodeficiency
synthetic tetravalent Man9GlcNAc cluster assembled onvirus type 1 (HIV-1) urges the development of an effective
a galactose scaffold was found to inhibit the binding ofHIV vaccine. Yet, it has been difficult to design effective
2G12 to gp120 more than 73-fold more effectively thanimmunogens that are able to elicit broadly neutralizing
antibodies against HIV-1 primary isolates [1–3]. HIV-1 the subunit Man9GlcNAc2Asn.
has evolved strategies such as frequent mutations of
neutralizing epitopes, heavy glycosylations, conforma-
tional changes, and formation of envelope spikes to Results and Discussion
evade immune attacks. So far, only a few human mono-
clonal antibodies (MAbs) that neutralize a broad range Binding of Homogeneous High-Mannose-Type
of HIV-1 primary isolates in vitro have been identified. Oligosaccharides to 2G12
Neutralizing antibodies 2F5 and 4E10 were found to A typical HIV-1 envelope glycoprotein gp120 bears 24
target epitopes on the inner-envelope glycoprotein gp41 asparagine-linked glycans (N-glycans). Among them, 11
[4–7], whereas neutralizing antibodies b12 and 2G12 are high-mannose- and/or hybrid-type oligosaccharides,
recognize epitopes on the outer-envelope glycoprotein and 13 are complex-type oligosaccharides [17]. Struc-
gp120 [8–12]. Passive immunization using these MAbs tural analysis indicated that high-mannose-type oligo-
either alone or in combination has shown that the neu- saccharides on HIV-1 gp120 are heterogeneous and
tralizing antibodies protect against HIV-1 challenge in range from Man5 to Man9 [18–20]. However, isolation of
animal models when they are present at sufficient con- individual high-mannose oligosaccharides directly from
centrations prior to or shortly after exposure [13, 14]. HIV-1 gp120 is technically difficult. To evaluate the affin-
Therefore, further characterization of the neutralizing ity of individual high-mannose-type glycoform for 2G12
interaction, we isolated three typical high-mannose-type
oligosaccharides, namely Man5GlcNAc, Man6GlcNAc, and*Correspondence: wangx@umbi.umd.edu
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Figure 2. Inhibition of 2G12 Binding to gp120 by High-Mannose-
Type Oligosaccharides
2G12 binding (percent) was plotted against the log of competing
carbohydrate concentrations in micromolar units. Triangles indicate
Man5GlcNAc; solid circles indicate Man6GlcNAc; and solid squares
indicate Man9GlcNAc.
(concentration for 50% inhibition) for Man9GlcNAc was
found to be 0.96 mM, whereas the IC50 for Man6GlcNAc
and Man5GlcNAc was estimated to be 70 and 200 mM,
respectively. Therefore, the Man9GlNAc is 74-fold and
210-fold more effective in inhibition of 2G12 binding
than Man6GlcNAc and Man5GlcNAc, respectively. On the
other hand, it was also found that the two Man9 struc-
tures, Man9GlcNAc and Man9GlcNAc2Asn, showed al-
most the same affinity for 2G12 binding (Table 1). This
suggests that the GlcNAc-Asn moiety linking the oligo-
saccharide and the protein portion is not directly in-
volved in the recognition with 2G12, which otherwise
could not be revealed through mutagenesis studies. The
much higher affinity of Man9GlcNAc to 2G12 than of
Man5GlcNAc and Man6GlcNAc to 2G12 implies the im-
portance of terminal Man1,2Man linkages in antibody
recognition. Our studies clearly indicate that antibody
Figure 1. Structures of Typical HIV-1 High-Mannose-Type Oligo- 2G12 preferably recognizes Man9 moiety among the oli-
saccharides gomannose glycoforms on HIV-1 gp120. In comparison,
Man9GlcNAc contains three terminal Man1,2Man link-
ages, and Man6GlcNAc contains one Man1,2Man link-
age, but Man5GlcNAc does not have any terminalMan9GlcNAc (Figure 1), with high purity from chicken
Man1,2Man linkage. It was previously reported thatovalbumin and soybean agglutinin, respectively. The
treatment of HIV-1 gp120 with mannosidases and high-mixture of Man5GlcNAc and Man6GlcNAc obtained by
mannose-specific endo-enzymes such as Endo H abol-sequential treatment of chicken ovalbumin with pro-
ished the binding of gp120 to antibody 2G12, suggestingnase and Arthrobactor endo--N-acetylglucosamini-
that the antibody binding is mannose dependent [15, 16].dase (Endo-A) was carefully separated on a Celite-Car-
Furthermore, treatment of gp120 with a special Aspergil-bon chromatography to afford each oligosaccharide.
lus saitoi mannosidase, which selectively hydrolyzesBased on HPAEC-PED analysis, the Man5GlcNAc and
Man1,2Man linkage without removing Man1,3 ManMan6GlcNAc thus isolated are at least 98% pure without
crosscontamination (data not shown). Similarly, ultra-
pure Man9GlcNAc was obtained through sequential di-
Table 1. Carbohydrate Inhibition of 2G12 Binding to gp120gestion of soybean agglutinin with pronase and Endo-A
and subsequent gel filtration on Sephadex G25 and re- Carbohydrate Antigens IC50 (mM) Relative Affinity
verse-phase HPLC purification.
Man5GlcNAc 200 (estimated) 0.005The affinity of the purified high-mannose oligosaccha- Man6GlcNAc 70 0.014
rides was examined by competitive inhibition of 2G12 Man9GlcNAc 0.96 1.0
binding to immobilized gp120 (Figure 2). It was observed Man9GlcNAc2Asn 0.95 1.0
Man9-dimer 0.40 2.4that the solubility of Man5GlCNAc and Man6GlcNAc
Bi-Man9 0.13 7.3in aqueous solution was unexpectedly low (less than
Tri-Man9 0.044 22.080 mM). As a result, the IC50 for Man5GlcNAc and
Tetra-Man9 0.013 73.0Man6GlcNAc cannot be accurately determined. The IC50
Carbohydrate Binding to Antibody 2G12
129
or Man1,6Man residues on gp120, also significantly remodeled N-glycans [23], the distances between the
reduced the binding of gp120 to 2G12, implying the asparagine (Asn) side chains of the pairs N295-N332,
importance of Man1,2Man residue in the carbohy- N332-N392, and N295-N392 are estimated to be 5.8,
drate-antibody recognition [16]. Our direct binding stud- 20.3, and 23.6 A˚, respectively. We have remodeled a
ies with individual oligosaccharides clearly indicate that Man9GlcNAc2Asn moiety on the previously synthesized
the larger high-mannose oligosaccharide Man9GlcNAc, galactose-based maleimide cluster [24] (MC-1, Figure
the affinity of which is 210- and 74-fold higher than 3) and found that the maleimide cluster can host four
that of Man5GlcNAc and Man6GlcNAc, is the favorable Man9GlcNAc2Asn moieties, in which the distances
subunit on gp120 for 2G12 recognition. Interestingly, among the Asn residues are in the range of 8–30 A˚ (data
another HIV-inactivating protein, cyanovirin-N, is also not shown). Therefore, the galactose-based maleimide
specific for larger high-mannose oligosaccharides such cluster should be a reasonable starting point for con-
as Man8 and Man9 on gp120 [21, 22]. However, it should structing the desired oligomannose clusters. If the first
be pointed out that although 2G12 and cyanovirin-N are set of synthetic oligosaccharide clusters were to show
both specific for Man9 structure on gp120 and show promising 2G12 binding properties, improved mimics
potent HIV-inactivating activity, cyanovirin-N binds to could be readily achievable by changing the length of
Man9 with a dissociation constant at a nanomolar scale, spacers on each arm and by reconfiguring the orienta-
whereas 2G12 binds to Man9 only on a millimolar scale tion of the sugar chains by using a different scaffold.
(Figure 2). It is clear that binding to a single subunit The key step in the synthesis is the chemoselective
high-mannose oligosaccharide is not sufficient for 2G12 maleimide cluster-thiol ligation reaction, which we have
to neutralize HIV. It seems that 2G12 enhances its bind- recently exploited for the synthesis of large multivalent
ing potency and specificity by recognizing a putative peptides and glycoconjugates [24, 25]. To introduce a
cluster of oligomannose sugar chains on gp120 [12, 15, sulfhydryl (SH) tag into the oligomannose moiety, we
16]. This was further demonstrated by the fact that cya- first acylated the free amino group in Man9GlcNAc2Asn
novirin-N efficiently inhibits 2G12 binding to gp120, with N-succinimidyl S-acetylthioacetate (SATA) [26] to
whereas 2G12 is not able to inhibit the binding of cya- give the N-(S-acetyl-thioacetyl) derivative. The S-acetyl
novirin-N to gp120 [15, 16]. group was then removed selectively by treatment with
hydroxylamine to afford the SH-containing oligosaccha-
ride Man9GlcNAc2Asn-Ac-SH. The synthesis of the tetra-Design and Synthesis of Oligomannose Clusters valent maleimide cluster MC-1 was previously reported.
as Mimics of 2G12 Epitope We synthesized the bi- and trivalent maleimide clusters
Mutagenesis studies and carbohydrate analyses of MC-2 and MC-3 (Figure 3) in a similar way by starting
2G12 epitope suggested that 2G12 recognizes a unique with modified galactoside scaffold (details of the synthe-
oligomannose cluster contributed mainly from the high- sis will be reported elsewhere). Chemoselective ligation
mannose-type oligosaccharides at the glycosylation between the Man9GlcNAc2Asn-Ac-SH and the malei-sites N295, N332, and N392, with other related oligosac-
mide cluster MC-1 was performed in a phosphate buffer
charides such as the glycans from N386, N339, or N448
(pH 6.6). HPLC monitoring indicated that the ligation
on the flank of the clusters [12, 15, 16]. Our binding
was quantitative and was complete within 1 hr at room
studies with an array of homogeneous high-mannose-
temperature to give the desired product, Tetra-Man9type oligosaccharides have demonstrated that the Man9 (Figure 3). Reverse-phase HPLC purification gave thesubunit is preferred over other HIV-1 high-mannose oli-
tetravalent oligomannose cluster Tetra-Man9 in 81%gosaccharides for 2G12 recognition. Therefore, oligo-
yield. The structure of Tetra-Man9 was characterized bymannose Man9 should be the “building block” of choice
electron spray ionization mass spectroscopy (ESI-MS)for creating mimics of the proposed epitope of 2G12.
(Figure 4). The ESI-MS spectrum revealed typical signalsWe reasoned that assembly of an oligomannose such
at 2435.35 (M  4H)4, 2395.15 (M  Man  4H)4,as Man9 on a suitable scaffold molecule should provide
1948.28 (M  5H)5, 1915.85 (M  Man  5H)5, andnovel oligosaccharide clusters that may mimic or cap-
1883.75 (M  2Man  5H)5, which are in agreementture 2G12 epitope as present on HIV-1 gp120. To test
with the structure. Similarly, the bi- and trivalent Man9the hypothesis, we synthesized bi-, tri- and tetra-valent
clusters Bi-Man9 and Tri-Man9 were synthesized throughMan9 clusters based on a galactopyranoside scaffold
ligation of Man9GlcNAc2Asn-Ac-SH with the maleimide(Figure 3). Compared to other types of molecules, mono-
clusters MC-2 and MC-3, respectively. On the othersaccharides have several advantages that help them
hand, a dimer of Man9GlcNAc2Asn was prepared throughserve as a scaffold. They have a rigid ring structure,
oxidation of Man9GlcNAc2Asn-Ac-SH to give the Man9possess multiple functionalities, and provide a defined
dimer (Figure 3). It should be noted that many glyco-three-dimensional spatial arrangement of substituents.
clusters were synthesized in recent years for studyingWhen a galactopyranoside is used as the scaffold to
the multivalent interaction and clustering effects in car-present the oligosaccharides, the oligosaccharide chains
bohydrate-protein recognition, but only a few involve thebeing installed at the C-3, -4, and -6 positions will face
synthesis of homogeneous, structurally defined glycoup above the sugar ring to form a cluster, whereas the
clusters of large oligosaccharides [27–31]. The methodoligomannose sugar chain at position C-2 is likely to be
described here should be equally applicable for synthe-located on the flank of the cluster. We expect that this
sizing various oligosaccharide clusters to probe the spa-arrangement will at least partially mimic the spatial ori-
tial requirement of subunit oligosaccharides in antibodyentation of the carbohydrate epitope of antibody 2G12.
Based on the reported structure of gp120 core with recognition.
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Figure 3. Structures of Galactose-Based Mmaleimide Clusters and Synthetic Oligomannose Clusters
Binding of the Synthetic Man9 Clusters to 2G12 (e.g., the new VH and VH interface) and creates new
binding sites for high-affinity multivalent interaction withThe synthetic Man9 clusters were examined for competi-
tive inhibition of 2G12 binding to immobilized gp120 a conserved cluster of oligomannose sugars on gp120.
The crystal structure suggested that a total of four high-(Figure 5). A significant clustering effect was observed
for the Man9 clusters in the binding studies. If IC50 is mannose oligosaccharide chains could be bound to the
domain-exchanged Fab dimer [32]. The new crystaltaken as an indication for relative affinity (Table 1), the
Tetra-Man9 was found to inhibit 2G12 binding to gp120 structure, together with molecular modeling studies, fur-
ther suggested that an oligomannose cluster composed73-fold more effectively than the monomeric Man9Glc-
NAc2Asn does on a molar basis. On the other hand, of sugar chains on N-glycosylation sites N332, N339,
and N392 was best fit for the binding to 2G12 [32]. Ourthe tri- and bivalent oligomannose clusters are 22- and
7-fold more effective than the monomeric Man9GlcNA- observed enhancement in 2G12 binding for the higher-
valent oligomannose clusters also suggests the exis-c2Asn in inhibition of 2G12 binding to gp120. The en-
hanced affinity for the clusters with higher valency sug- tence of additional binding sites on 2G12 for carbohy-
drate antigen. Another interesting finding in our bindinggests that antibody 2G12 may have multiple binding
sites for the carbohydrate antigen. During the prepara- studies came from the two bivalent oligomannose com-
pounds, Bi-Man9 and Man9 dimer. The Bi-Man9 is 3-foldtion of this manuscript, Calarese et al. [32] reported the
crystal structures of Fab 2G12 and its complex with more effective than Man9 dimer in inhibition of 2G12
binding to gp120. The results suggest that the controloligosaccharide Man9GlcNAc2. The X-ray structural stud-
ies revealed that two Fab fragments in 2G12 assemble of geometry and distance between the subunits is im-
portant for a tight, multivalent interaction between theinto an extraordinary VH domain-swapped dimer, in
which the VH domain is exchanged with VH domain to carbohydrate antigen and the antibody. However, it
should be noted that the relative affinity of the currentinteract with VL and vice versa. This unusual configura-
tion of antibody domains provides an extended surface synthetic clusters is still much lower than the affinity of
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immunogen. Work along this line is in progress and will
be reported in due course.
Significance
It has been proposed that the broadly neutralizing anti-
body recognizes a unique cluster of high-mannose
oligosaccharides on HIV-1 gp120 [12, 15, 16]. The
unique oligomannose cluster formed on the so-called
immunologically “silent face” of gp120, which was not
found on normal human glycoproteins, may be re-
garded as “non-self” and, therefore, provides an at-
tractive target for HIV-1 vaccine design. However,
HIV-1 gp120 expresses heterogeneous high-mannose
oligosaccharides ranging from Man5 to Man9 on these
glycosylation sites [18–20]. The diverse oligomannose
glycoforms of HIV-1 gp120 may dilute any potential
immune response to the epitope. This may partially
explain why gp120 itself can hardly raise 2G12-like
antibodies. As an initial step toward the design of a
vaccine that mimics 2G12s epitope, we first studied
Figure 4. The HPLC and ESI-MS Profiles of the Synthetic Tetrava- the binding of an array of homogeneous high-mannose
lent Oligomannose Cluster Tetra-Man9 oligosaccharides with 2G12 and found that the Man9
structure is the best subunit for 2G12 recognition, im-
plying the structural importance of terminal Man1,2Man
gp120 for 2G12. The IC50 for the best mimic, Tetra-Man9, linkages in 2G12s epitope. To mimic the clustering
is at micromolar level, whereas the IC50 for gp120 is in epitope of 2G12, we then designed and synthesized
the middle of the nanomolar range in our assay (data several structurally defined oligomannose clusters
not shown). Therefore, the present study provides the based on a galactose scaffold. Our binding studies
first-generation synthetic oligosaccharide clusters in an with the synthetic oligomannose clusters revealed an
attempt to mimic the putative epitope of 2G12 for HIV apparent clustering effect of the oligomannose clus-
vaccine design. Apparently, the logical next step should ters, with the higher-valent clusters binding to 2G12
optimize the spatial orientation of oligomannose sugar better than the lower-valent oligomannose clusters.
chains by changing the length of spacers, as well as The enhanced affinity for the clusters with higher va-
the rigidity and configuration of the scaffold. The avail- lency suggests that antibody 2G12 may have multiple
ability of the crystal structure of 2G12 now will facilitate binding sites for the carbohydrate antigen. Coinci-
more rational design of template-assembled oligoman- dently, the most recently solved X-ray structure of
nose clusters. Finally, because the synthetic oligoman- 2G12 reveals that 2G12 creates additional binding sites
nose clusters themselves are likely to be poorly immuno- for multivalent interaction with the carbohydrate anti-
genic, they will be conjugated to a carrier protein or gen by taking an extraordinary, VH domain-swapped
to a universal T-helper epitope to provide a functional antibody structure [32]. The first generation of syn-
thetic oligomannose clusters described in this paper
serves as a basis for further optimization of synthetic
mimics of 2G12 epitope. Conjugation of the synthetic
epitope mimics to a carrier protein should provide
a functional immunogen that may raise neutralizing
antibodies specific for the high-mannose oligosac-
charides on gp120, which may eventually lead to a
carbohydrate-based synthetic vaccine for HIV-1.
Experimental Procedures
Materials
Monosaccharides, pronase, Sephadex, trifluoroacetic acid, and re-
agents for ELISAs and buffers were purchased from Sigma-Aldrich
and used as received. N-succinimidyl S-acetylthioacetate was from
Pierce Chemical Company. HPLC grade acetonitrile was purchased
from Fisher Scientific. The immobilized endo--N-acetyl-glucosami-
Figure 5. Inhibition of 2G12 Binding to gp120 by Synthetic Oligo- nidase from Arthrobactor (Endo-A) was overproduced and purified
mannose Clusters according to the literature [33].
2G12 binding (percent) was plotted against the log of competing
carbohydrate concentrations in micromolar units. Solid diamonds High-Performance Liquid Chromatography
Unless otherwise specified, analytical high-performance liquid chro-indicate Man9GlcNAc2Asn; open triangles indicate Man9-dimer; solid
triangles indicate Bi-Man9; open circles indicate Tri-Man9; and solid matography (HPLC) was carried out on a Waters 626 HPLC instru-
ment under the following conditions: column, Waters Nova-Pak C18circles indicate Tetra-Man9.
Chemistry & Biology
132
(3.9  150 mm); temperature, 40C; and flow rate, 1 ml/min. The Man  2H)2, 837.68 (M  2Man  2H)2, 756.70 (M  3Man 
2H)2, 675.52 (M  4Man  2H)2, 594.61 (M  5Man  2H)2.column was eluted with a linear gradient of acetonitrile (0%–50%)
containing 0.1% TFA in 25 min with UV detection at 214 nm. Prepara-
tive HPLC was performed on a Waters 600 HPLC instrument with
Man9GlcNAca preparative C18 column (Waters Symmetry 300, 19  300 mm).
HPAEC-PED, tR 16.9 min; ESI-MS, calcd. for C62H105NO51: 1679.57.The column was eluted with a suitable gradient of water-acetonitrile
Found: 1680.80 (M  H), 1518.64 (M  Man  H), 1356.72 (M 
containing 0.1% TFA.
2Man  H), 1194.54 (M  3Man  H), 1032.60 (M  4Man  H),
841.36 (M  2H)2.
High-Performance Anion Exchange Chromatography
Coupled with Pulsed Electrochemical Detection
Man6GlcNAcThe analytical anion-exchange chromatography was performed on
HPAEC-PED, tR 15.9 min; ESI-MS, calculated for C44H75NO36: 1193.41.a Dionex DX600 chromatography system (Dionex Corporation, Sun-
Found: 1216.84 (M  Na), 1194.81 (M  H), 608.99 (M  2Na)2.nyvale, CA) equipped with an electrochemical detector (ED50, Dio-
nex Corporation, Sunnyvale, CA). The following conditions were
used: column, CarboPac-PA1 (4  250 mm); eluent A, 0.1 M NaOH;
Man5GlcNAceluent B, 1 M sodium acetate (NaOAc) in 0.1 M NaOH; gradient: 0–5
HPAEC-PED, tR 15.3 min; ESI-MS, calculated for C38H65NO31: 1031.35.min, 0% B; 5-25 min, 0%–15% B; flow rate, 1 ml/min.
Found: 1054.70 (M  Na), 1032.79 (M  H), 528.07 (M  2Na)2.
Competitive Enzyme-Linked Immunosorbent Assays
Preparation of the SH-Tagged Man9 OligosaccharideWe performed competitive ELISAs to determine the relative inhibi-
tion potency of various carbohydrate antigens against the binding A solution of N-succinimidyl S-acetylthioacetate [26] (22 mg) in ace-
of 2G12 to gp120. Microtiter plates were coated with human cell tonitrile (0.5 ml) was added to a solution of Man9GlcNAc2Asn (32
line 293-expressed HIV-1IIIB gp120 (100 ng/ml) overnight at 4C. After mg) in a phosphate buffer (3 ml, pH 7.4) containing 20% acetonitrile.
plates were washed, nonspecific binding was blocked with 5% BSA The mixture was stirred at room temperature for 1 hr and lyophilized.
in PBS for 1 hr at room temperature. The plates were then washed The product was purified by reverse-phase HPLC to give the
three times with 0.1% Tween-20/PBS. Serial dilutions (1:2) of various N-(S-acetyl-thioacetyl) Man9GlcNAc2Asn derivative (26 mg): analyti-
carbohydrate antigens were mixed with an equal volume of mAb cal HPLC (gradient: 0%–30% acetonitrile containing 0.1% TFA in
2G12 (fixed final concentration of 5 ng/ml) and added to the plates. 25 min; flow rate, 1 ml/min), tR 6.3 min; ESI-MS, 2114.55 (M  H),
The plates were incubated for 1 hr at 37C and washed with washing 1057.66 (M  2H)2, 976.55 (M  Man  2H)2, 895.45 (M  2Man 
buffer. To the plates was added a 100 l solution of 1:3000 diluted 2H)2, 815.54 (M 3Man 2H)2, 733.43 (M 4Man 2H)2, 652.39
horseradish peroxidase-conjugated goat anti-human IgG in 0.5% (M  5Man  2H)2, 571.34 (M  6Man  2H)2]. A solution of the
BSA/PBS. After incubation for 1 hr at 37C, the plates were washed N-(S-acetyl-thioacetyl) derivative (20 mg) in a phosphate buffer (2
again, and a 100 l solution of 3,3,5,5-tetramethyl benzidine (TMB) ml, 50 mM, pH 7.4) containing hydroxylamine (50 mM) was stirred
was added. Color was allowed to develop for 5 min, and the reaction at room temperature for 2 hr, and the De-S-acetylated product was
was quenched by the addition of a 100 l solution of 0.5 M H2SO4 directly purified by reverse-phase HPLC to give the SH-tagged oligo-
to each well. The optical density was then measured at 450 nm. saccharide Man9GlcNAc2Asn-Ac-SH (15 mg), which was character-
ized by HPLC and ESI-MS. Analytical HPLC (gradient: 0%–30%
Preparation of Homogeneous High-Mannose-Type acetonitrile containing 0.1% TFA in 25 min, flow rate, 1 ml/min), tR
Oligosaccharides 2.7 min; ESI-MS, 2072.56 (M  H), 1036.71 (M  2H)2, 955.68
Man9GlcNAc2Asn and Man9GlcNAc were prepared by enzymatic di- (M  Man  2H)2, 874.71 (M  2Man  2H)2, 793.66 (M  3Man 
gestion of soybean agglutinin and subsequent chromatographic pu- 2H)2, 712.56 (M 4Man 2H)2, 631.51 (M 5Man 2H)2, 550.66
rification. Crude soybean agglutinin (3.2 g) was obtained from 500 (M  6Man  2H)2.
g of soybean flour (Sigma) through fractional precipitation with am-
monium sulfate and digested thoroughly with pronase (2  15 mg,
Synthesis of Tetravalent Oligomannose ClusterSigma) according to the literature [34]. The digestion was filtered,
To a solution of Man9GlcNAc2Asn-Ac-SH (7.60 mg, 3.67 mol) in aand the filtrate was lyophilized. The residue was loaded onto a
phosphate buffer (pH 6.6, 50 mM, 1.2 ml) was added a solution ofcolumn (1.5 70 cm) of Sephadex G50 (Sigma), which was preequili-
the galactose-based maleimide cluster MC-1 (0.67 mg, 0.46 mol)brated and eluted with 0.1 M AcOH. The fractions containing Man9Gl-
in acetonitrile (0.8 ml). The mixture was gently shaken at room tem-cNAc2Asn were pooled and lyophilized. The material was finally
perature under nitrogen atmosphere for 1 hr. The mixture was thenpurified by reverse-phase HPLC to afford homogeneous Man9Glc-
lyophilized. The ligation product was purified by reverse-phaseNAc2Asn (55 mg) as a white powder after lyophilization. Treatment
HPLC to afford Tetra-Man9 (3.60 mg, 81%). Analytical HPLC, tR, 16.1of Man9GlcNAc2Asn (20 mg) with immobilized Arthrobactor endo-
min; ESI-MS, 2435.35 (M  4H)4, 2395.15 (M  Man  4H)4,-N-acetylglucosaminidase (Endo-A) in an acetate buffer (pH 6.0),
1948.28 (M  5H)5, 1915.85 (M  Man  5H)5, and 1883.75 (M and subsequent gel filtration on a column (1.5 50 cm) of Sephadex
2Man  5H)5, which are in agreement with its structure.G25 gave pure Man9GlcNAc (12 mg), which was characterized by
compositional analysis, HPLC, and electron spray ionization mass
spectrometry (ESI-MS). Synthesis of Trivalent Oligomannose Cluster
Homogeneous Man5GlcNAc and Man6GlcNAc were obtained from The trivalent maleimide cluster MC-3 (1.0 mg) and Man9GlcNAc2Asn-
pronase digestion of chicken ovalbumin and subsequent chromato- Ac-SH (8.0 mg) were reacted in the same way as for the preparation
graphic purification. Chicken ovalbumin (Sigma) was digested with of Tetra-Man9. The ligation product was purified by reverse-phase
pronase to provide a crude mixture of Man5- and Man6-containing HPLC to give the Tri-Man9 (7.3 mg, 82%). Analytical HPLC, tR, 15.5
glycopeptides, according to the literature [35]. A crude glycopeptide min; ESI-MS: 2457.90 (M3H)3, 1843.64 (M  4H)4, 1802.92 (M 
(350 mg) was treated with immobilized Endo-A to release Man5Glc- Man4H)4, 1762.68 (M  2Man  4H)4, 1722.10 (M  3Man 
NAc and Man6GlcNAc as a mixture. The two oligosaccharides were 4H)4, 1681.79 (M  4Man  4H)4.
then separated by chromatography on a column (1  125 cm) of
Celite-Charcoal (1:1, w/w), which was eluted by a gradient of 0%–
Synthesis of Bivalent Oligomannose Cluster20% aqueous ethanol to give pure Man5GlcNAc (25 mg) and pure
The bivalent maleimide cluster MC-2 (1.3 mg) and Man9GlcNAc2Asn-Man6GlcNAc (30 mg). The purity of the above isolated oligosaccha-
Ac-SH (9.4 mg) were reacted in the same way as for the preparationrides was confirmed by HPAEC-PED, and their identity was charac-
of Tetra-Man9. The ligation product was purified by reverse-phaseterized by ESI-MS.
HPLC to give Bi-Man9 (6.1 mg, 80%). Analytical HPLC, tR, 15.4 min;
ES-MS, 2502.12 (M2H)2, 1668.22 (M 3H)3, 1614.19 (MManMan9GlcNAc2Asn
3H)3, 1560.24 (M  2Man  3H)3, 1506.01 (M  3Man  3H)3,HPAEC-PED, tR 17.1 min; ESI-MS: calculated for C74H124N4O58:
1997.77. Found: 1998.73 (M  H), 999.69 (M  2H)2, 918.65 (M  1452.54 (M  4Man  3H)3.
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Preparation of Man9 Dimer Allaway, G.P., Katinger, H., Barbas, C.F., 3rd, Burton, D.R., Ho,
D.D., et al. (1995). Cross-clade neutralization of primary isolatesMan9GlcNAc2Asn-Ac-SH (8 mg) was dissolved in a phosphate buffer
(2 ml, 50 mM, pH 7.5), and air was bubbled into the solution for 10 of human immunodeficiency virus type 1 by human monoclonal
antibodies and tetrameric CD4-IgG. J. Virol. 69, 6609–6617.min. The solution was kept at room temperature overnight. The
oxidized product thus formed was purified by reverse-phase HPLC 12. Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher,
A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J.P., andto give the Man9 dimer (5.6 mg). Analytical HPLC (gradient: 0%–30%
acetonitrile containing 0.1% TFA in 25 min; flow rate, 1 ml/min), tR Katinger, H. (1996). Human monoclonal antibody 2G12 defines
a distinctive neutralization epitope on the gp120 glycoprotein5.3 min; ESI-MS, 2072.0 (M  2H)2, 1381.6 (M  3H)3, 1327.5 (M 
Man  3H)3, 1273.4 (M  2Man  3H)3, 1219.45 (M  3Man  of human immunodeficiency virus type 1. J. Virol. 70, 1100–1108.
13. Mascola, J.R., Stiegler, G., VanCott, T.C., Katinger, H., Carpen-3H)3, 1165.41 (M  4Man  3H)3, 1111.2 (M  5Man  3H)3.
ter, C.B., Hanson, C.E., Beary, H., Hayes, D., Frankel, S.S., Birx,
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